Pioneering a new class of programmable
mRNA-encoded therapeutics
Our platform
Platform capabilities
Topology of Genomic Control
Omega understands the topology and the functionality of IGDs through both computational and biological insights and leverages our diverse library of proprietary algorithms and deep-learning techniques to categorize the roughly 15,000 human IGDs.
Biology of Disease
We are linking disease biology pathways with the appropriate IGDs for therapeutic intervention, precisely targeting those that control both single-gene and multigene disorders. We understand how they differ between pristine and diseased states, and these insights inform the Company’s approach to IGDs as drug targets to treat and potentially cure serious disease.
Precision Therapeutics
We are designing, engineering and manufacturing Omega Epigenomic Controllers™ to target EpiZips for the cell types of interest, with the ability to specifically downregulate or upregulate genomic activity for therapeutic effect.
Our pipeline
We are advancing a robust pipeline to drive company value and demonstrate the breadth and depth of our science.
| Target Gene(s)/EpiZip(s) | Disease(s) | OEC | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|---|---|---|---|---|
| Oncology | ||||||||
|
MYC
H3B.08.qX.Y.Z.930
Hepatocellular Carcinoma
OEC:OTX-2002*
|
Preclinical | Hepatocellular Carcinoma | OTX-2002* | |||||
|
MYC
H2009.08.qX.Y.Z.930
Non-Small Cell Lung Cancer
OEC:OTX-2101
|
Discovery | Non-Small Cell Lung Cancer | OTX-2101 | |||||
|
Undisclosed
Small Cell Lung Cancer
|
Discovery | Small Cell Lung Cancer | ||||||
| Multigenic Diseases Incl. Immunology | ||||||||
|
CXCL 1-8
A549.04.qX.Y.Z.533
Potential Franchise of Programs**
|
Discovery | Potential Franchise of Programs** | ||||||
|
Undisclosed
Idiopathic Pulmonary Fibrosis
|
Discovery | Idiopathic Pulmonary Fibrosis | ||||||
| Regenerative Medicine | ||||||||
|
HNF4A
HEP.20.qX.Y.Z.552
Liver Regeneration
|
Preclinical | Liver Regeneration | ||||||
|
Undisclosed
Corneal Regeneration
|
Discovery | Corneal Regeneration | ||||||
| Select Monogenic Diseases | ||||||||
|
SFRP1
HFDP.08.pX.Y.Z.644
Alopecia
|
Preclinical | Alopecia | ||||||
|
Route of Administration (top to bottom): IV (Liver Regeneration),
Topical (Corneal Regeneration), IV/Pulminary (ARDS / COVID 19), IV/Pulminary (IPF),
IV (HCC), IV (NSCLC), IV (SCLC), Topical (Alopecia)
*In November 2022, OTX-2002 received Orphan Drug Designation from the FDA for the treatment of hepatocellular carcinoma **Potential indications for CXCL-targeting OEC include neutrophilic asthma, acute respiratory distress syndrome (including COVID-related), oncology, and dermatological and rheumatological indications |
||||||||
Partner with omega
Omega develops novel engineered therapeutics that precisely tune genomic expression of single, multiple and historically 'undruggable' gene targets, to desired therapeutic levels with high specificity and durability of effect: That's what we call Precision Genomic Control™
